Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.

ABSTRACT:

Background

This clinical trial evaluated whether topotecan in combination with bevacizumab improved progression-free survival (PFS) in patients with advanced, refractory non--small-cell lung cancer in a second-line setting.

Patient and methods

Patients aged 18 years old and older received topotecan (4.0 mg/m(2)) on days 1, 8, and 15, and bevacizumab (10 mg/kg) on days 1 and 15 as intravenous infusions on a 28-day treatment cycle. Available tumor specimens were analyzed for ISG15 gene expression as a biomarker of response to topotecan.

Results

Forty-two patients were enrolled in the study, with a median age of 62.5 years and a median of 3 (range, 1-7) prior treatment regimens. Almost half (n = 18, 42.9%) of the patients received prior bevacizumab therapy. PFS was 5.1 m

SUBMITTER: Powell SF 

PROVIDER: S-EPMC4524809 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature